0

Close
 
Upcoming Allied Market Research
2023
Cholesterol-lowering Drug Market

Cholesterol-lowering Drug Market

by Drug Class (Statins, Bile Acid Sequestrants, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Others) and by Disease type (Hypercholesterolemia, Cardiovascular Diseases, Hyperlipidemiav): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A05144
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cholesterol-lowering Drug Market

Request Now !

Cholesterol is an organic molecule that belongs to the group of steroids and is a type of lipid. It is biosynthesized by all animal cells, and is an essential structural component of animal cell membranes. The significance of cholesterol is the biosynthesis of steroid hormones such as estrogen and testosterone, as well as bile acid and vitamin D. About 80% of cholesterol production occurs in liver and intestines, and the rest comes from dietary sources such as meat, poultry, eggs, fish, and dairy products. Although cholesterol is fundamentally required by the body, more than 240 mg/dl is considered as high cholesterol. A total cholesterol of 200 mg/dl or lower is acceptable, and 200–240 mg/dl is considered borderline high. This elevated level of cholesterol in the blood is termed as hypercholesterolemia. High cholesterol may be a consequence of unhealthy diet, obesity, genetic diseases, or other diseases such as type 2 diabetes and an underactive thyroid. 

The global cholesterol lowering drug market is anticipated to grow modestly during the forecast period. Some of the factors anticipated to boost the cholesterol lowering drug market growth are emergence of new drug classes, changes in lifestyles, lack of exercise, and increase in intake of saturated & trans-fat. In addition, increase in smoking and alcohol consumption escalate the risk of high cholesterol, thus driving the market growth. However, severe side effects of statins causing rhabdomyolysis and availability of generic drugs of leading brands are projected to restrain the market growth during the forecast period. On the contrary, lucrative opportunities in emerging economies are expected to provide significant prospects for the manufacturers in industry.

Emergence of more effective therapies such as PCSK9 inhibitors, bempedoic acid, and the upcoming drug by The Medicines Company, inclisiran is anticipated to expand the range of clinical indications. Inclisiran is an upcoming drug, which may enter the market by 2020, and is expected to become the third potent drug after the two PCSK9 inhibitors, Repatha (Amgen) and Praluent (Sanofi/Regeneron). Former CEO of the Medicines Company, Dr. Clive Meanwell indicated that the company is likely to keep cost lower than that of PCSK9 inhibitors to bring the medicine to the masses. Furthermore, inclisiran has significant advantage over the two, for its requirement of only 2 dose per year. For comparison, PCSK9 needs to be dosed every two weeks.

This report segments the cholesterol-lowering drug market based on drug class, disease type, and region. Depending on drug class, the market can be classified as statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination, and others. By disease type, it categorized into hypercholesterolemia, cardiovascular diseases, and hyperlipidemia. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

The report provides a comprehensive analysis of the key players operating in the global cholesterol lowering drug market players such as AstraZeneca, Merck & Co., Pfizer Inc., Kowa Company, Daiichi Sankyo Company, Limited, AbbVie Inc., Novartis AG, Sanofi S.A., Amgen Inc., and Bristol-Myers Squibb (BMS). The other players in the value chain includes Covis Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Bausch Health Companies Inc., Aegerion Pharmaceuticals, Aralez Pharmaceuticals, and others.

KEY BENEFITS FOR STAKEHOLDERS

  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global cholesterol lowering drugs market is provided.
  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current trends and future market potential in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the cholesterol lowering drugs market are profiled in this report, and their strategies are analyzed thoroughly, which helps to understand the competitive outlook of global cholesterol lowering drugs market.  

 Cholesterol-lowering Drug Market Report Highlights

Aspects Details
By Drug Class
  • Statins
  • Bile Acid Sequestrants
  • PCSK9 Inhibitors
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • Combination
  • Others
By Disease type
  • Hypercholesterolemia
  • Cardiovascular Diseases
  • Hyperlipidemiav
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Kowa Company, Novartis AG, AbbVie Inc., Daiichi Sankyo Company Limited, Merck & Co., Bristol-Myers Squibb (BMS), Amgen Inc., Sanofi S.A., AstraZeneca, Pfizer Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: CHOLESTEROL-LOWERING DRUG MARKET, BY DRUG CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Class

    • 4.2. Statins

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Bile Acid Sequestrants

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. PCSK9 Inhibitors

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Cholesterol Absorption Inhibitors

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Fibric Acid Derivatives

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Combination

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Others

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

  • CHAPTER 5: CHOLESTEROL-LOWERING DRUG MARKET, BY DISEASE TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease Type

    • 5.2. Hypercholesterolemia

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Cardiovascular Diseases

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Hyperlipidemiav

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: CHOLESTEROL-LOWERING DRUG MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Drug Class

      • 6.2.3. Market Size and Forecast, By Disease Type

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Cholesterol-lowering Drug Market

        • 6.2.5.1. Market Size and Forecast, By Drug Class
        • 6.2.5.2. Market Size and Forecast, By Disease Type

      • 6.2.6. Canada Cholesterol-lowering Drug Market

        • 6.2.6.1. Market Size and Forecast, By Drug Class
        • 6.2.6.2. Market Size and Forecast, By Disease Type

      • 6.2.7. Mexico Cholesterol-lowering Drug Market

        • 6.2.7.1. Market Size and Forecast, By Drug Class
        • 6.2.7.2. Market Size and Forecast, By Disease Type

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Drug Class

      • 6.3.3. Market Size and Forecast, By Disease Type

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Cholesterol-lowering Drug Market

        • 6.3.5.1. Market Size and Forecast, By Drug Class
        • 6.3.5.2. Market Size and Forecast, By Disease Type

      • 6.3.6. Germany Cholesterol-lowering Drug Market

        • 6.3.6.1. Market Size and Forecast, By Drug Class
        • 6.3.6.2. Market Size and Forecast, By Disease Type

      • 6.3.7. Italy Cholesterol-lowering Drug Market

        • 6.3.7.1. Market Size and Forecast, By Drug Class
        • 6.3.7.2. Market Size and Forecast, By Disease Type

      • 6.3.8. Spain Cholesterol-lowering Drug Market

        • 6.3.8.1. Market Size and Forecast, By Drug Class
        • 6.3.8.2. Market Size and Forecast, By Disease Type

      • 6.3.9. UK Cholesterol-lowering Drug Market

        • 6.3.9.1. Market Size and Forecast, By Drug Class
        • 6.3.9.2. Market Size and Forecast, By Disease Type

      • 6.3.10. Russia Cholesterol-lowering Drug Market

        • 6.3.10.1. Market Size and Forecast, By Drug Class
        • 6.3.10.2. Market Size and Forecast, By Disease Type

      • 6.3.11. Rest Of Europe Cholesterol-lowering Drug Market

        • 6.3.11.1. Market Size and Forecast, By Drug Class
        • 6.3.11.2. Market Size and Forecast, By Disease Type

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Drug Class

      • 6.4.3. Market Size and Forecast, By Disease Type

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Cholesterol-lowering Drug Market

        • 6.4.5.1. Market Size and Forecast, By Drug Class
        • 6.4.5.2. Market Size and Forecast, By Disease Type

      • 6.4.6. Japan Cholesterol-lowering Drug Market

        • 6.4.6.1. Market Size and Forecast, By Drug Class
        • 6.4.6.2. Market Size and Forecast, By Disease Type

      • 6.4.7. India Cholesterol-lowering Drug Market

        • 6.4.7.1. Market Size and Forecast, By Drug Class
        • 6.4.7.2. Market Size and Forecast, By Disease Type

      • 6.4.8. South Korea Cholesterol-lowering Drug Market

        • 6.4.8.1. Market Size and Forecast, By Drug Class
        • 6.4.8.2. Market Size and Forecast, By Disease Type

      • 6.4.9. Australia Cholesterol-lowering Drug Market

        • 6.4.9.1. Market Size and Forecast, By Drug Class
        • 6.4.9.2. Market Size and Forecast, By Disease Type

      • 6.4.10. Thailand Cholesterol-lowering Drug Market

        • 6.4.10.1. Market Size and Forecast, By Drug Class
        • 6.4.10.2. Market Size and Forecast, By Disease Type

      • 6.4.11. Malaysia Cholesterol-lowering Drug Market

        • 6.4.11.1. Market Size and Forecast, By Drug Class
        • 6.4.11.2. Market Size and Forecast, By Disease Type

      • 6.4.12. Indonesia Cholesterol-lowering Drug Market

        • 6.4.12.1. Market Size and Forecast, By Drug Class
        • 6.4.12.2. Market Size and Forecast, By Disease Type

      • 6.4.13. Rest of Asia Pacific Cholesterol-lowering Drug Market

        • 6.4.13.1. Market Size and Forecast, By Drug Class
        • 6.4.13.2. Market Size and Forecast, By Disease Type

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Drug Class

      • 6.5.3. Market Size and Forecast, By Disease Type

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Cholesterol-lowering Drug Market

        • 6.5.5.1. Market Size and Forecast, By Drug Class
        • 6.5.5.2. Market Size and Forecast, By Disease Type

      • 6.5.6. South Africa Cholesterol-lowering Drug Market

        • 6.5.6.1. Market Size and Forecast, By Drug Class
        • 6.5.6.2. Market Size and Forecast, By Disease Type

      • 6.5.7. Saudi Arabia Cholesterol-lowering Drug Market

        • 6.5.7.1. Market Size and Forecast, By Drug Class
        • 6.5.7.2. Market Size and Forecast, By Disease Type

      • 6.5.8. UAE Cholesterol-lowering Drug Market

        • 6.5.8.1. Market Size and Forecast, By Drug Class
        • 6.5.8.2. Market Size and Forecast, By Disease Type

      • 6.5.9. Argentina Cholesterol-lowering Drug Market

        • 6.5.9.1. Market Size and Forecast, By Drug Class
        • 6.5.9.2. Market Size and Forecast, By Disease Type

      • 6.5.10. Rest of LAMEA Cholesterol-lowering Drug Market

        • 6.5.10.1. Market Size and Forecast, By Drug Class
        • 6.5.10.2. Market Size and Forecast, By Disease Type

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. AstraZeneca

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Merck And Co.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Pfizer Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Kowa Company

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Daiichi Sankyo Company Limited

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. AbbVie Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Novartis AG

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Sanofi S.A.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Amgen Inc.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Bristol-Myers Squibb (BMS)

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR STATINS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR BILE ACID SEQUESTRANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR PCSK9 INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR CHOLESTEROL ABSORPTION INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR FIBRIC ACID DERIVATIVES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR COMBINATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET FOR HYPERLIPIDEMIAV, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA CHOLESTEROL-LOWERING DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 17. U.S. CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 18. U.S. CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 19. CANADA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 20. CANADA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE CHOLESTEROL-LOWERING DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 27. FRANCE CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 30. ITALY CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 31. ITALY CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 33. SPAIN CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 34. UK CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 35. UK CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 36. RUSSIA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 37. RUSSIA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 39. REST OF EUROPE CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC CHOLESTEROL-LOWERING DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 42. ASIA-PACIFIC CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 43. CHINA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 44. CHINA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 46. JAPAN CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 47. INDIA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 48. INDIA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 49. SOUTH KOREA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 51. AUSTRALIA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 52. AUSTRALIA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 53. THAILAND CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. THAILAND CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 55. MALAYSIA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. MALAYSIA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 57. INDONESIA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 58. INDONESIA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA CHOLESTEROL-LOWERING DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 63. LAMEA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 64. BRAZIL CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 65. BRAZIL CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH AFRICA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH AFRICA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SAUDI ARABIA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. SAUDI ARABIA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 70. UAE CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 71. UAE CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 72. ARGENTINA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 73. ARGENTINA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 74. REST OF LAMEA CHOLESTEROL-LOWERING DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 75. REST OF LAMEA CHOLESTEROL-LOWERING DRUG, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 76. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 77. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 78. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 79. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 80. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. MERCK AND CO.: KEY EXECUTIVES
  • TABLE 82. MERCK AND CO.: COMPANY SNAPSHOT
  • TABLE 83. MERCK AND CO.: OPERATING SEGMENTS
  • TABLE 84. MERCK AND CO.: PRODUCT PORTFOLIO
  • TABLE 85. MERCK AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. PFIZER INC.: KEY EXECUTIVES
  • TABLE 87. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 88. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 89. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 90. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. KOWA COMPANY: KEY EXECUTIVES
  • TABLE 92. KOWA COMPANY: COMPANY SNAPSHOT
  • TABLE 93. KOWA COMPANY: OPERATING SEGMENTS
  • TABLE 94. KOWA COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. KOWA COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. DAIICHI SANKYO COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 97. DAIICHI SANKYO COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 98. DAIICHI SANKYO COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 99. DAIICHI SANKYO COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 100. DAIICHI SANKYO COMPANY LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 102. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 103. ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 104. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 105. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 107. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 108. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 109. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 110. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 112. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 113. SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 114. SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 115. SANOFI S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. AMGEN INC.: KEY EXECUTIVES
  • TABLE 117. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 118. AMGEN INC.: OPERATING SEGMENTS
  • TABLE 119. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 120. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. BRISTOL-MYERS SQUIBB (BMS): KEY EXECUTIVES
  • TABLE 122. BRISTOL-MYERS SQUIBB (BMS): COMPANY SNAPSHOT
  • TABLE 123. BRISTOL-MYERS SQUIBB (BMS): OPERATING SEGMENTS
  • TABLE 124. BRISTOL-MYERS SQUIBB (BMS): PRODUCT PORTFOLIO
  • TABLE 125. BRISTOL-MYERS SQUIBB (BMS): KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CHOLESTEROL-LOWERING DRUG MARKET
  • FIGURE 3. SEGMENTATION CHOLESTEROL-LOWERING DRUG MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CHOLESTEROL-LOWERING DRUG MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCHOLESTEROL-LOWERING DRUG MARKET
  • FIGURE 11. CHOLESTEROL-LOWERING DRUG MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 12. CHOLESTEROL-LOWERING DRUG MARKET FOR STATINS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CHOLESTEROL-LOWERING DRUG MARKET FOR BILE ACID SEQUESTRANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CHOLESTEROL-LOWERING DRUG MARKET FOR PCSK9 INHIBITORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. CHOLESTEROL-LOWERING DRUG MARKET FOR CHOLESTEROL ABSORPTION INHIBITORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. CHOLESTEROL-LOWERING DRUG MARKET FOR FIBRIC ACID DERIVATIVES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CHOLESTEROL-LOWERING DRUG MARKET FOR COMBINATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. CHOLESTEROL-LOWERING DRUG MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. CHOLESTEROL-LOWERING DRUG MARKET SEGMENTATION, BY BY DISEASE TYPE
  • FIGURE 20. CHOLESTEROL-LOWERING DRUG MARKET FOR HYPERCHOLESTEROLEMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. CHOLESTEROL-LOWERING DRUG MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. CHOLESTEROL-LOWERING DRUG MARKET FOR HYPERLIPIDEMIAV, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: CHOLESTEROL-LOWERING DRUG MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. MERCK AND CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. MERCK AND CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. MERCK AND CO.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. KOWA COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. KOWA COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. KOWA COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. DAIICHI SANKYO COMPANY LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. DAIICHI SANKYO COMPANY LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. DAIICHI SANKYO COMPANY LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. ABBVIE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. ABBVIE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. SANOFI S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. SANOFI S.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. AMGEN INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. AMGEN INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. BRISTOL-MYERS SQUIBB (BMS): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. BRISTOL-MYERS SQUIBB (BMS): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. BRISTOL-MYERS SQUIBB (BMS): REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Cholesterol-lowering Drug Market

Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers